HHS OIG: Listing of Pharmaceutical and Device Corporate Integrity Agreements

Below is a list in alphabetic order of the major pharmaceutical and medical device manufacturer corporate integrity agreements (CIAs) entered into with the Office of the Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS).  For reader’s reference, most CIAs are typically for five (5) years, so the close date will be approximately five years from the start date, unless the manufacturer has violated the terms of its CIA or entered into a second or third CIA. 

# Company Start Date End Date or Closed
1. Abbot Laboratories

 

5/7/2012  
2. Allergan

 

8/30/2010  
3. Amgen Inc.

 

12/14/2012  
4. AstraZeneca LP

 

4/27/2010  
5. Sanofi Aventis

 

8/30/2007 Closed 1/28/2013
6. Bayer Healthcare LLC

 

11/25/2008  
7. Biomet, Inc

 

9/27/2007  Closed 1/9/2013
8. Biovail Corp n/k/a Valeant Pharmacetucals International

 

9/11/2009  
9. Boehringer Ingelheim Pharmaceuticals Inc

 

10/22/2012  
10. Boston Scientific Corp.

 

12/23/2009  
11. Bristol Myers Squibb Company

 

9/26/2007  Closed 12/12
12. Cephalon, Inc. (Teva)

 

9/29/2008  
13. Cell Therapeutics, Inc.

 

12/22/2007  
14. Depuy Orthopaedics, Inc.

 

9/27/2007 Closed 2/01/2013
15. Elan Corp

 

12/15/2010  
16. Eli Lilly and Co.

 

1/14/2009  
17. Forest Labs

 

 

9/15/2010  
18. GlaxoSmithKline

 

6/28/2012  
19. Ivax Pharmaceuticals, Inc.

 

10/30/2009  
20. Medtronic

 

5/31/2009  New 9/5/2013
21. Merck & Co, Inc.

 

11/22/2011  
22. Novartis Pharmaceuticals Corp

 

9/29/2010  
23. Novo Nordisk Inc.

 

5/31/2011  
24. Ortho-McNeil-Janssen Pharmaceuticals, Inc.

 

06/06/2012  
25. Orthofix International, N.V.

 

4/28/2010  
26. Otsuka America Pharmaceutical, Inc.

 

3/25/2008  New 9/18/2013
27. Pfizer, Inc.

 

8/31/2009  
28. Purdue Pharma L.P.

 

7/31/2007 Closed 1/23/2013
29. Quest Diagnostics, Inc.

 

4/14/2009  
30. Synthes, Inc.

 

9/23/2010  
31. UCB, Inc.

 

5/24/2011  
32. Wright Medical Technology

 

9/29/2010  
NEW
Comments (0)
Add Comment